Viewing nowJadis 25 mg Tablets (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
Hana Pharmaceutical Co., Ltd.

MFDS item code 202102089 · Approved 2021.03.05 · Insurance code 657808320
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to help control blood sugar in adults with type 2 diabetes mellitus. It can be administered alone, and when blood sugar control is difficult with monotherapy, it may be used in combination with metformin or other diabetes medications. Additionally, it is used in conjunction for patients who do not achieve sufficient blood sugar control with insulin treatment or multiple combined therapies. It is important to refer to clinical trial information from experts regarding its efficacy in preventing cardiovascular events in patients with cardiovascular diseases. This medication is effectively used for improving blood sugar control in patients with type 2 diabetes.
The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well and whose glomerular filtration rate remains below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. This medicine should not be used in patients with end-stage renal disease (ESRD) or patients on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment because it has not been studied in this population. •Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiating treatment with this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).
This medication should not be administered to patients who are allergic to the active ingredient or any components. It should not be used in patients with type 1 diabetes or those with diabetic ketoacidosis. Patients with severely impaired renal function, end-stage kidney disease, or those undergoing dialysis should not take this medication. Due to the presence of lactose, it should not be administered to patients with genetic conditions such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption. Patients with weak renal function require careful dosage adjustments, and treatment should be discontinued if renal function worsens significantly. Patients with mild to moderate heart failure should use caution, and it is not recommended for patients with severe heart failure. When used concurrently with insulin or insulin secretagogues, there may be a risk of hypoglycemia, necessitating dosage adjustments. The most common side effects of this medication include hypoglycemia, genital infections, increased urination, and urinary tract infections. Particularly, hypoglycemia may occur more frequently when used in combination with insulin or sulfonylureas, thus monitoring is necessary. Serious metabolic disturbances such as ketoacidosis may occur rarely and require immediate treatment if symptoms arise. Elderly patients or those at risk of fluid loss should be closely monitored for dehydration or hypotension. There have been reports of serious urinary tract infections such as urosepsis or pyelonephritis, so prompt treatment is required if infection symptoms are present. This medication may increase the risk of genital fungal infections; thus, appropriate management is necessary if related symptoms are present. Its use is not recommended during pregnancy, and treatment should be halted if pregnancy is confirmed. Breastfeeding should also be avoided while taking this medication. Safety and efficacy in children under 18 years have not been established. No special toxic symptoms have been reported in cases of overdose, but appropriate treatment is required based on clinical conditions. This medication may have a slight effect on driving or operating machinery, especially in individuals at risk for hypoglycemia, necessitating caution. Regular monitoring of kidney function and checking fluid status and electrolyte balance is important during treatment with this medication. Furthermore, diabetic patients should pay attention to routine foot care and infection prevention, and if pain or abnormal symptoms occur around the perineum, immediate consultation with healthcare professionals is advised.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. Additionally, it is advisable to avoid very hot or very cold places and to store it at temperatures between 1 to 30 degrees Celsius.
Light yellow, bidirectional convex oval film-coated tablets
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 25mg
Tablet · Prescription medication
Hana Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.